Frontline Management of Atopic Dermatitis in Adults - Episode 10
LIBERTY AD Open-Label Extension Analysis: Takeaways and Considerations
Panelists discuss how The LIBERTY AD OLE study (Beck 2024) showed sustained efficacy of treatment in atopic dermatitis, with 96.9% achieving EASI-50; 88.9%, EASI-75; and 80.7%, EASI-90 over 260 weeks. Common adverse events (AEs) included nasopharyngitis, atopic dermatitis (AD) worsening, upper respiratory tract infections, herpes infections, and conjunctivitis. Treatment-emergent adverse event (TEAE)–related withdrawal was 3.8%.
Video content above in prompted by the following:
- Can you discuss the notable findings from the LIBERTY AD OLE study (Beck 2024) and how they are relevant to you and your practice?
- Of the 326 subjects who remained in the trial for 260 weeks, 96.9% achieved EASI-50; 88.9%, EASI-75; and 80.7%, EASI-90.
- Most common AEs were nasopharyngitis, worsening AD, upper respiratory tract infection, herpes viral infections, and conjunctivitis
- 101/2677 (3.8%) of patients in the safety analysis set withdrew due to TEAEs.
